Navigation Links
PROLOR Biotech To Present Preclinical Data On Its Long-Acting Clotting Factor Vlla At 2012 ASH Annual Meeting
Date:12/7/2012

ATLANTA and NES-ZIONA, Israel, Dec. 7, 2012 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH), today announced that the company will present preclinical data on its long-acting clotting Factor VIIa (Factor Vlla-CTP) at the 54th Annual Meeting of the American Society of Hematology (ASH).  The data will be discussed by Dr. Gili Hart, Director of Pre-Clinical Affairs at PROLOR and head of the company's long-acting clotting factors program, in an oral poster presentation on December 8, 2012.  PROLOR's Factor VIIa-CTP is in advanced preclinical development for the treatment of hemophilia.

Top-line results of the Factor Vlla-CTP studies have been previously reported by PROLOR. The results show that when compared to commercially available Factor VIIa, Factor VIIa-CTP in hemophilic mice demonstrated a markedly enhanced pharmacokinetic profile and increased exposure, as evidenced by a prolonged hemostatic effect and improved recovery, which is a measure of clotting activity.  Compared to commercially available Factor VIIa, Factor VIIa-CTP in hemophilic mice demonstrated superior thrombin generation parameters, and it resulted in greater survival of the subjects.  In these studies, the specific activity of Factor VIIa-CTP was comparable to commercial Factor VIIa.  The study data also show that administration of Factor Vlla-CTP by subcutaneous injection resulted in improved bioavailability and prolonged exposure compared to intravenous administration of Factor Vlla-CTP.

PROLOR CEO Dr. Abraham Havron commented, "The ASH Annual Meeting is the largest and most prominent gathering of hematology experts in the world.  In preclinical studies our long-acting clotting factors have demonstrated the potential to significantly improve both the prophylactic and on-demand treatment of patients with hemophilia, and we welcome the opportunity to share these promising data with leading hematology researchers."

Dr. Hart will presen
'/>"/>

SOURCE PROLOR Biotech, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. GenWay Biotech Appoints New Vice President of Custom/OEM
2. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
3. Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.
4. Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis
5. TaiGen Biotechnology Out-Licensed China Rights of Novel Antibiotic, Nemonoxacin, to Zhejiang Medicine
6. Lifeline Biotechnologies, Inc. Receives Patent Award, a Device for Breast Tissue Temperature Analysis for Determining Cancer Conditions
7. Obamacare Ruling, Other Pivotal News Rocks Biotech Sector in June
8. Tougher Times May be Ahead for Biotechs: 1H12 Fundraising Slows
9. Last Chance to Save on Boston-Area Mobile Health, Biotech, and Pharmaceutical Conference Registration
10. Early Birds Save Up to $600 on Asian Biotech and Pharmaceutical Conferences
11. Lifeline Biotechnologies First Warning Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... N.Y. , May 22, 2013  MGT Capital ... Company will present at the Second Annual Marcum LLP ... New York City at the Grand ... and Chief Executive Officer, will update investors and answer ... The Company,s presentation is scheduled to begin at ...
(Date:5/22/2013)... MAPLE GROVE, Minn. , May 22, ... today announced the successful completion of its ... (extended-release topiramate), an internally developed program for ... the company,s proprietary formulation technology.  USL255 is ... and reduce fluctuations in topiramate blood levels ...
(Date:5/22/2013)... , May 22, 2013 Hemoglobin A1C ... patients with Type 2 diabetes, while modest improvements ... health outcomes and can lead to substantial healthcare ... the International Society for Pharmacoeconomics and Outcomes Research ... two studies, sponsored by Valeritas, makers of the ...
Breaking Medicine Technology:MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 3MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 4Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 2Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 3Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 4Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 2Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 3Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 4Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 5Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 6
... designed for more uniform drug ... ... Boston,Scientific Corporation (NYSE: BSX ) today announced comprehensive data ... historically controlled trials, which evaluate,the TAXUS(R) Liberte(R) Paclitaxel-Eluting Stent System in ...
... with Kogenate FS Reduces the,Risk of Joint Damage ... Damage, BERKELEY, Calif., Oct. 10 Bayer ... Drug Administration (FDA) has,approved routine prophylaxis with Kogenate(R) ... bleeding episodes and the risk of,joint damage in ...
Cached Medicine Technology:Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 2Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 3Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 4Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 5Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 6FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 2FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 3FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 4FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 5
(Date:5/22/2013)... 22, 2013 CoCENTRIX, a leading ... Health and Human Services and community providers, announced ... (ADMH) selected the CoCENTRIX Coordinated Care Platform ... the Health Records and coordinate care within and ... , CoCENTRIX is transitioning the hospitals' official records ...
(Date:5/22/2013)... 22, 2013 LDM Global ( http://www.ldmglobal.com ... services for law firms, corporations and government agencies announces ... cloud-based e-discovery software company, to deliver defensible ESI collections ... partnership, Cumulus Data and LDM Global hosted a VIP ... Tuesday, May 21st. This event was in conjunction ...
(Date:5/22/2013)... May 22, 2013 BroadConnect Telecom, ... and IT security solutions in North America announced ... of its newest BroadConnect hosted security solutions. Available ... hybrid combination, BroadConnect’s new Security as a Service ... the Internet connection of their choice, while optimizing ...
(Date:5/22/2013)... Poor adherence to appropriate medication therapy has ... and death (some 125,000 deaths in the U.S. every ... costs. It’s been estimated that between 33% and 69% ... medication adherence — a reality that costs the American ... dire is the degree of medication non-adherence — and ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Mari’s Skin Care, ... has become the first in the state of Texas to ... Meta Therapy- Medical and Esthetic Tissue Activation, also known as ... over four years in Europe, but has just recently made ... improves the skin from inside out by building collagen and ...
Breaking Medicine News(10 mins):Health News:The State of Alabama Selects the CoCENTRIX Coordinated Care Platform to Facilitate Care for Its Citizens Treated in State Psychiatric Hospitals 2Health News:The State of Alabama Selects the CoCENTRIX Coordinated Care Platform to Facilitate Care for Its Citizens Treated in State Psychiatric Hospitals 3Health News:LDM Global Enhances Forensic Data Collection Services with eCloudCollect 2Health News:LDM Global Enhances Forensic Data Collection Services with eCloudCollect 3Health News:BroadConnect Telecom to Launch Enterprise-Grade Hosted Security Solutions Engineered to Meet the Demands of Real World Business 2Health News:Patient Prompt® Announces New Drug Adherence Program to Assist in Prescribed Medication Compliance 2Health News:Mari's to Offer New Treatment from Europe 2
... to a new report by the UNH scientist, the beginning ... The effect, which is a result of global warming, has ... a ripple effect in all the happenings takes place in ... March 20th marking the vernal equinox and the official start ...
... a simple and natural remedy for reducing the intensity ... // by just eating more fruits and vegetables. They ... antioxidants, are capable of accelerating and worsening an attack. ... to a diet low in antioxidants and their asthma ...
... of seagrass beds around the world has resulted ... and sediment stabilizers affecting the shallow-water ecosystems // ... resources and marine science, University of New Hampshire. ... deeply affected even the commercially valuable valuable shellfish ...
... have discovered how to measure the absorption of multi-walled ... nanotubes were discovered in 1991, and have a great ... storage in fuel cells. But despite their promise, a ... carbon nanotubes will impact the living environment. This discovery ...
... release on the 28th regarding a study on stethoscope accuracy ... that physicians with more experience // are better able to ... heart disease. The researchers felt that with a greater experience ... pathologic heart disorders., ,Publishing their findings in the March ...
... The New York State Department of Health has confirmed coliform ... by North Country Spring Water//, Ltd. For this reason ... recalling all of its bottled water products. Coliform bacteria ... presence of coliform bacteria in bottled water is a violation ...
Cached Medicine News:Health News:‘Natural Spring’ Starts A Week Ahead Now Than Before: UNH Scienti 2Health News:‘Natural Spring’ Starts A Week Ahead Now Than Before: UNH Scienti 3Health News:Global Seagrass Decline Affects Shallow-water Ecosystems 2Health News:Global Seagrass Decline Affects Shallow-water Ecosystems 3Health News:Absorption Of Carbon Nanotube Measured In Worms Revolutionize Cancer Research 2Health News:Experienced Physicians Diagnose Heart Disease’s Earlie 2
... a 1-step, hand-held, point-of-care device for the qualitative ... urine. The TOX/See device can detect up ... in 3 to 8 minutes and requires only ... is individually packaged to maximize convenience and ease ...
... hand-held, point-of-care device for the qualitative detection of ... The TOX/See device can detect up to nine ... to 8 minutes and requires only a few ... packaged to maximize convenience and ease of use. ...
... TOX/See™ is a 1-step, hand-held, point-of-care device for ... in human urine. The TOX/See device can ... abused drugs in 3 to 8 minutes and ... TOX/See cassette is individually packaged to maximize convenience ...
... TOX/See™ is a 1-step, hand-held, point-of-care device for ... in human urine. The TOX/See device can ... abused drugs in 3 to 8 minutes and ... TOX/See cassette is individually packaged to maximize convenience ...
Medicine Products: